Section Arrow
Quote
ENVB.NASDAQ
- Enveric Biosciences Inc.
Quotes are at least 15-min delayed:2026/01/04 22:16 EST
Regular Hours
Last
 3.67
+0.04 (+1.10%)
Day High 
3.75 
Prev. Close
3.63 
1-M High
13.25 
Volume 
43.19K 
Bid
3.65
Ask
3.8
Day Low
3.5 
Open
3.61 
1-M Low
3.6 
Market Cap 
3.82M 
Currency 美元 
P/E 0 
%Yield -- 
10-SMA 4.56 
20-SMA 5.41 
50-SMA 5.92 
52-W High 96.3 
52-W Low 1.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1,390.68/-1.41
Enterprise Value
3.82M
Balance Sheet
Book Value Per Share
3.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.